A Safety Extension Study with Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist - MELTEMI

Study identifier:D3250C00037

ClinicalTrials.gov identifier:NCT02808819

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicenter, Open-label, Safety Extension Study with Benralizumab (MEDI-563) for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist (MELTEMI)

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

447

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 30 Jun 2016
Primary Completion Date: 18 Jun 2020
Study Completion Date: 18 Jun 2020

Study design

Allocation: Non-randomized
Endpoint Classification: Safety
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Other

Verification:

Verified 01 Mar 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria